These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

266 related items for PubMed ID: 9732389

  • 1. Antiplatelet efficacy of XV459, a novel nonpeptide platelet GPIIb/IIIa antagonist: comparative platelet binding profiles with c7E3.
    Mousa SA, Bozarth JM, Lorelli W, Forsythe MS, Thoolen MJ, Slee AM, Reilly TM, Friedman PA.
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1277-84. PubMed ID: 9732389
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Platelet GPIIb/IIIa antagonist, XV459, in heparin-induced thrombocytopenia.
    Mousa SA, Ahmad S.
    Am J Hematol; 2007 Apr; 82(4):276-82. PubMed ID: 17039513
    [Abstract] [Full Text] [Related]

  • 5. Oral antiplatelet efficacy and specificity of a novel nonpeptide platelet GPIIb/IIIa receptor antagonist, DMP 802.
    Mousa SA, Olson RE, Bozarth JM, Lorelli W, Forsythe MS, Racanelli A, Gibbs S, Schlingman K, Bozarth T, Kapil R, Wityak J, Sielecki TM, Wexler RR, Thoolen MJ, Slee A, Reilly TM, Anderson PS, Friedman PA.
    J Cardiovasc Pharmacol; 1998 Aug; 32(2):169-76. PubMed ID: 9700976
    [Abstract] [Full Text] [Related]

  • 6. Oral antiplatelet efficacy of the platelet GPIIb/IIIa antagonist, DMP754 in non-human primates.
    Mousa SA, Bozarth J, Youssef A, Levine B.
    Thromb Res; 1998 Mar 01; 89(5):217-25. PubMed ID: 9645915
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of platelet-mediated clot retraction by integrin antagonists.
    Hantgan RR, Mousa SA.
    Thromb Res; 1998 Mar 15; 89(6):271-9. PubMed ID: 9669749
    [Abstract] [Full Text] [Related]

  • 8. Intravenous and oral antithrombotic efficacy of the novel platelet GPIIb/IIIa antagonist roxifiban (DMP754) and its free acid form, XV459.
    Mousa SA, Kapil R, Mu DX.
    Arterioscler Thromb Vasc Biol; 1999 Oct 15; 19(10):2535-41. PubMed ID: 10521384
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparative in vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet-mediated clot strength induced by tissue factor with use of thromboelastography: differentiation among glycoprotein IIb/IIIa antagonists.
    Mousa SA, Khurana S, Forsythe MS.
    Arterioscler Thromb Vasc Biol; 2000 Apr 15; 20(4):1162-7. PubMed ID: 10764688
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Orally active isoxazoline glycoprotein IIb/IIIa antagonists with extended duration of action.
    Olson RE, Sielecki TM, Wityak J, Pinto DJ, Batt DG, Frietze WE, Liu J, Tobin AE, Orwat MJ, Di Meo SV, Houghton GC, Lalka GK, Mousa SA, Racanelli AL, Hausner EA, Kapil RP, Rabel SR, Thoolen MJ, Reilly TM, Anderson PS, Wexler RR.
    J Med Chem; 1999 Apr 08; 42(7):1178-92. PubMed ID: 10197962
    [Abstract] [Full Text] [Related]

  • 13. Identification of low molecular weight GP IIb/IIIa antagonists that bind preferentially to activated platelets.
    Bednar RA, Gaul SL, Hamill TG, Egbertson MS, Shafer JA, Hartman GD, Gould RJ, Bednar B.
    J Pharmacol Exp Ther; 1998 Jun 08; 285(3):1317-26. PubMed ID: 9618439
    [Abstract] [Full Text] [Related]

  • 14. New orally active non-peptide fibrinogen receptor (GpIIb-IIIa) antagonists: identification of ethyl 3-[N-[4-[4-[amino[(ethoxycarbonyl) imino]methyl]phenyl]-1,3-thiazol-2-yl]-N-[1-[(ethoxycarbonyl)methyl]pip erid -4-yl]amino]propionate (SR 121787) as a potent and long-acting antithrombotic agent.
    Badorc A, Bordes MF, de Cointet P, Savi P, Bernat A, Lalé A, Petitou M, Maffrand JP, Herbert JM.
    J Med Chem; 1997 Oct 10; 40(21):3393-401. PubMed ID: 9341914
    [Abstract] [Full Text] [Related]

  • 15. The fibrinogen gamma chain dodecapeptide inhibits agonist-induced aggregation of rabbit platelets and fibrinogen binding to rabbit glycoprotein IIb-IIIa.
    Rand ML, Packham MA, Taylor DM, Yeo EL, Gemmell CH, Patil S, Lam SC.
    Thromb Haemost; 1999 Dec 10; 82(6):1680-6. PubMed ID: 10613655
    [Abstract] [Full Text] [Related]

  • 16. Intravenous and oral antiplatelet/antithrombotic efficacy and specificity of XR300, a novel nonpeptide platelet GPIIb/IIIa antagonist.
    Mousa SA, Forsythe M, Wityak J, Bozarth J, Mu DX.
    J Cardiovasc Pharmacol; 1998 Mar 10; 31(3):441-8. PubMed ID: 9514190
    [Abstract] [Full Text] [Related]

  • 17. Prevention of platelet glycoprotein IIb/IIIa activation by 3,4-methylenedioxy-beta-nitrostyrene, a novel tyrosine kinase inhibitor.
    Wang WY, Wu YC, Wu CC.
    Mol Pharmacol; 2006 Oct 10; 70(4):1380-9. PubMed ID: 16837624
    [Abstract] [Full Text] [Related]

  • 18. Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates, and microparticles in vitro.
    Matzdorff AC, Kühnel G, Kemkes-Matthes B, Pralle H, Voss R, Fareed J.
    J Lab Clin Med; 2000 Mar 10; 135(3):247-55. PubMed ID: 10711863
    [Abstract] [Full Text] [Related]

  • 19. In-vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists and thrombolytics on platelet/fibrin-mediated clot dynamics in human whole blood using thrombelastography.
    Mousa SA.
    Blood Coagul Fibrinolysis; 2007 Jan 10; 18(1):55-60. PubMed ID: 17179828
    [Abstract] [Full Text] [Related]

  • 20. Differential antiplatelet efficacy for various GPIIb/IIIa antagonists: role of plasma calcium levels.
    Mousa SA, Bozarth JM, Forsythe MS, Slee A.
    Cardiovasc Res; 2000 Sep 10; 47(4):819-26. PubMed ID: 10974231
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.